Sartorius has unveiled a cutting-edge genetically engineered CHO host cell line, promising significant advancements in productivity and efficiency for biopharmaceutical development. This innovative line emerged from a meticulous process combining proteomic profiling and targeted genome editing, as highlighted by a representative from Sartorius.
Improved Productivity
The new CHO host cell line underwent extensive evaluation across various cell line development (CLD) campaigns, demonstrating remarkable improvements in productivity metrics. When tested at a five-liter bioreactor scale, the engineered host exhibited up to a two-fold increase in expression titers. Furthermore, it achieved up to three times the productivity of lead clones derived from the traditional wild-type CHO host under conventional fed-batch processes. Notably, these gains occurred without compromising product quality, with consistent performance observed across diverse therapeutic proteins, including IgG1, IgG4, Fc-fusion, and bispecific antibodies.
Optimized Bioprocessing
In the realm of intensified bioprocessing, the engineered CHO host line showcases its ability to support superior titers and extended culture durations in continuous perfusion systems. Oscar Reif, the head of corporate research and CTO at Sartorius, emphasizes this capability. For a chosen clone expressing a monoclonal antibody, the team recorded a two-fold increase in daily titers while maintaining high cell density and viability levels exceeding 80 percent over a culture duration of up to 28 days. This breakthrough paves the way for more sustainable and efficient biomanufacturing practices.
Long-Term Reliability
Reliability is a cornerstone of the new CHO host cell line’s design. Sartorius reports that over 90 percent of the evaluated clones exhibited consistent protein expression while sustaining a low gene copy number through more than 70 generations. This remarkable stability not only enhances long-term manufacturing consistency but also bolsters regulatory confidence, crucial for biopharmaceutical production.
Unprecedented Performance
Reif asserts that this engineered CHO host cell line represents a landmark achievement in the CLD market. It is, to the best of their knowledge, the first of its kind to deliver such exceptional performance levels. This breakthrough has the potential to reshape the landscape of biopharmaceutical production, offering new avenues for researchers and manufacturers alike.
Implications for Biotech
The introduction of this advanced CHO host cell line signifies a pivotal moment in bioprocessing technology. As the demand for effective and efficient biopharmaceuticals continues to grow, the ability to produce high-quality therapeutics at scale becomes increasingly critical. This development not only enhances productivity but also assures the reliability needed for regulatory compliance.
Future Directions
As Sartorius continues to push the boundaries of host cell engineering, the implications of this technology are expansive. The combination of advanced genetic engineering techniques and rigorous testing opens doors to further innovations that could transform biopharmaceutical development.
Key Takeaways
- Sartorius has launched a genetically engineered CHO host cell line that doubles expression titers and triples productivity compared to traditional lines.
- The new cell line supports high cell density and viability over extended culture durations, enhancing overall bioprocess sustainability.
-
Over 90 percent of evaluated clones maintain consistent protein expression and low gene copy numbers, ensuring long-term manufacturing reliability.
In conclusion, the introduction of Sartorius’s advanced CHO host cell line marks a significant leap forward in biopharmaceutical production technology. With its impressive productivity and reliability metrics, this innovation stands poised to redefine industry standards and drive future breakthroughs in therapeutic development.
Read more → www.genengnews.com